SULFAMIDE, N-(((2S)-6-CHLORO-2,3-DIHYDRO-1,4-BENZODIOXIN-2-YL)METHYL)-
Photosensitive Epilepsy
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.Small moleculePhase 2Dormant
CCC
55/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 40/ 100
- Competitive Position
- 95/ 100
Competitive context
1 Active assets in the Photosensitive Epilepsy cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Valproic Acid Vanderbilt University Medical Center | Phase 4 | BB |
Benzeneethanamine, N-ethyl-?-methyl-4-(trifluoromethyl)-, hydrochloride, (±)- Elizabeth Anne Thiele | Phase 3 | BB |
SELURAMPANEL Novartis Pharmaceuticals | Phase 2 | B |
Carbamazepine The Epilepsy Study Consortium | Phase 2 | B |
Act-709478 For Use Idorsia Pharmaceuticals Ltd. | Phase 2 | B |
View all 10 →
Same molecule, other indications
SULFAMIDE, N-(((2S)-6-CHLORO-2,3-DIHYDRO-1,4-BENZODIOXIN-2-YL)METHYL)- is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →